Aerin to rollout VIVAER for overcoming nasal airway obstruction

It is to be taken into account that Aerin Medical has been granted clearance for its novel non-invasive Airway Remodeling System termed as VIVAER to overcome nasal airway barriers thus enabling physicians to treat them without entailing incisions or implants. With the financial aid of $25 million by KCK Group and Horizon Finance Corporation, the company eyes the launch of its product.

Estimates suggest an average of 20 million people suffer from nasal airway obstruction in the United States alone. The treatment options available presently are invasive thus failing to provide long-lasting relief to patients thus Aerin’s non- invasive solution offers quality cure for patients afflicted with disruptive nasal breathing without having to undertake a surgery. Aerin has completed clinical trials that manifested the efficacy and safety of VIVAER marking commendable improvement in almost 94% of the patients. European post-market data reveals persistent mitigation of the symptoms thus hinting at improvement.

Scott Wolf, MD, Founder and Chief Medical Officer, stated “The principal complaint of patients visiting ENT physicians is typically a ‘stuffy’ or ‘blocked’ nose. Until now, many of these patients would have been offered invasive surgery or treated medically with nasal sprays or nasal breathing strips until their symptoms worsened sufficiently to warrant surgery. Now, with the availability of the VIVAER procedure, these patients can be treated in their ENT’s office with a 15-20-minute, non-invasive, office-based procedure and immediately return to work breathing better.”

Image Source: Aerin Medical